4D Molecular Therapeutics, Inc. (FDMT)

NASDAQ: FDMT · IEX Real-Time Price · USD
21.26
+1.03 (5.09%)
At close: Jan 27, 2023, 4:00 PM
21.69
+0.43 (2.02%)
After-hours: Jan 27, 2023, 7:49 PM EST
5.09%
Market Cap 688.66M
Revenue (ttm) 1.97M
Net Income (ttm) -105.20M
Shares Out 32.39M
EPS (ttm) -3.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 218,052
Open 20.23
Previous Close 20.23
Day's Range 19.87 - 21.30
52-Week Range 5.32 - 26.49
Beta 2.75
Analysts Buy
Price Target 36.72 (+72.72%)
Earnings Date Mar 27, 2023

About FDMT

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which i... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. John F. Milligan Ph.D.
Employees 140
Stock Exchange NASDAQ
Ticker Symbol FDMT
Full Company Profile

Financial Performance

In 2021, FDMT's revenue was $18.04 million, an increase of 32.52% compared to the previous year's $13.61 million. Losses were -$71.32 million, 25.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is $36.72, which is an increase of 72.72% from the latest price.

Price Target
$36.72
(72.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs

EMERYVILLE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted g...

2 weeks ago - GlobeNewsWire

4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference

EMERYVILLE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic...

2 months ago - GlobeNewsWire

4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why

4D Molecular's (FDMT) progress with the development of its pipeline candidates in cystic fibrosis and wet AMD indications have been significant catalysts for the stock.

2 months ago - Zacks Investment Research

4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)

EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted g...

2 months ago - GlobeNewsWire

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022

4D Molecular Therapeutics to host a conference call on November 14th, 8:00 am E.T. 4D Molecular Therapeutics to host a conference call on November 14th, 8:00 am E.T.

2 months ago - GlobeNewsWire

4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results

- Interim clinical trial data from 4DMT's Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at North American Cystic Fibrosis Conference on November 3,...

2 months ago - GlobeNewsWire

4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022

EMERYVILLE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted g...

3 months ago - GlobeNewsWire

Strength Seen in 4D Molecular Therapeutics, Inc. (FDMT): Can Its 16.0% Jump Turn into More Strength?

4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest furth...

3 months ago - Zacks Investment Research

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022

4D Molecular Therapeutics to host a conference call on November 3rd, 4:30 pm E.T. 4D Molecular Therapeutics to host a conference call on November 3rd, 4:30 pm E.T.

3 months ago - GlobeNewsWire

4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer

EMERYVILLE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted ...

4 months ago - GlobeNewsWire

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted ...

4 months ago - GlobeNewsWire

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -11.54% and 94.60%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for t...

6 months ago - Zacks Investment Research

4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update

- Five clinical-stage product candidates on track for multiple clinical data updates in 2023

6 months ago - GlobeNewsWire

4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences

EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted g...

8 months ago - GlobeNewsWire

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12.33% and 39.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for ...

9 months ago - Zacks Investment Research

4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted ge...

9 months ago - GlobeNewsWire

Analysts Estimate 4D Molecular Therapeutics, Inc. (FDMT) to Report a Decline in Earnings: What to Look Out for

4D Molecular Therapeutics, Inc. (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference

EMERYVILLE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted ...

9 months ago - GlobeNewsWire

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis

EMERYVILLE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for ta...

10 months ago - GlobeNewsWire

4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights

EMERYVILLE, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted ...

10 months ago - GlobeNewsWire

4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company's Board of Directors

EMERYVILLE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene thera...

1 year ago - GlobeNewsWire

4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

EMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) --  4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gen...

1 year ago - GlobeNewsWire

4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium

EMERYVILLE, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...

1 year ago - GlobeNewsWire

6 Underperforming IPO Stocks To Buy On The Dip

The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last...

Other symbols: FWRGNRDSOMICPRCTVECT
1 year ago - Benzinga

4D Molecular Therapeutics to Present Updated Clinical Data with 4D-310 in Fabry Disease Patients in Platform Presentation at the 18th Annual WORLDSymposium

EMERYVILLE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene thera...

1 year ago - GlobeNewsWire